Leflunomide Tablet
Product Images NDC 46708-437

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Leflunomide (NDC 46708-437). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30's Bottle Pack (Leflunomide 10mg)

This is a medication label for Lefunomide tablets containing 10mg of the medication. Dosage instructions and storage conditions are mentioned. The packaging has a child-resistant cap and a tamper-evident seal. The medication is manufactured by Alembic Pharmaceuticals in Gujarat, India. The label includes the batch number, expiry date, and a National Drug Code (NDC) for the tablets. The medication is available only with a prescription.*

FDA Label Image

30's Bottle Pack (Leflunomide 20mg)

Each film-coated tablet contains Lefunomide USP 20mg. Dosage and Administration instructions are available in the package insert. Store the tablets at a temperature between 25°C and 30°C (77°F to 86°F) and protect them from light. This package has a tamper-evident cap and is child-resistant. The tablets are manufactured by Alembic Pharmaceutical Limited in India. The product is available in packages of 30 tablets and requires a prescription. The lot number and expiration date are not available.*

FDA Label Image

Figure 1 (Leflunomide Figure1)

This is a table showing the percentage of ACR 20 responders at different endpoints in three trials. The trials are identified by Trial 1, Trial 2, and Trial 3, and the time periods measured are 6 months and 12 months. The treatments being tested are Methotrexate and placebo. No further information is available.*

FDA Label Image

Figure 2 (Leflunomide Figure2)

This appears to be a chart or graph showing the percentage of ACR (American College of Rheumatology) responders over time in Trial 1. The data is likely presented in a visual format with a Y-axis representing the percentage of responders and an X-axis representing time. The specific data points and trends cannot be determined without the graphic itself.*

FDA Label Image

Figure 3 (Leflunomide Figure3)

FDA Label Image

Figure 4 (Leflunomide Figure4)

The text describes a change in functional ability measure over a period of 12 months, including improvement. The measure is likely related to the HAQ Disability Index, although it is unclear what the LMPLsPL represents. The rest of the text is not understandable.*

FDA Label Image

Structure (Leflunomide Metabolite)

FDA Label Image

Structure (Leflunomide Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.